Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Shares Issued (2016 - 2025)

Historic Shares Issued for Viking Therapeutics (VKTX) over the last 11 years, with Q4 2025 value amounting to $1.2 million.

  • Viking Therapeutics' Shares Issued rose 1550.0% to $1.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 million, marking a year-over-year decrease of 7696.29%. This contributed to the annual value of $2.5 million for FY2025, which is 7696.29% down from last year.
  • As of Q4 2025, Viking Therapeutics' Shares Issued stood at $1.2 million, which was up 1550.0% from $436000.0 recorded in Q3 2025.
  • In the past 5 years, Viking Therapeutics' Shares Issued ranged from a high of $5.7 million in Q1 2021 and a low of $5000.0 during Q3 2021
  • In the last 5 years, Viking Therapeutics' Shares Issued had a median value of $807000.0 in 2022 and averaged $1.6 million.
  • Examining YoY changes over the last 5 years, Viking Therapeutics' Shares Issued showed a top increase of 344000.0% in 2021 and a maximum decrease of 9757.28% in 2021.
  • Over the past 5 years, Viking Therapeutics' Shares Issued (Quarter) stood at $66000.0 in 2021, then soared by 127.27% to $150000.0 in 2022, then increased by 12.0% to $168000.0 in 2023, then skyrocketed by 495.24% to $1.0 million in 2024, then increased by 15.5% to $1.2 million in 2025.
  • Its Shares Issued stands at $1.2 million for Q4 2025, versus $436000.0 for Q3 2025 and $551000.0 for Q2 2025.